Opinion: Global investors must support pharma solidarity and collaboration in the response to Covid-19
The prospect of having the first supplies of at least a few effective Covid-19 medicines and vaccines by the end of 2020 is a key driver of recent market optimism. New treatments and vaccines are among the best bets for our societies against the risk of recurring Covid-19 flare-ups and persistent lockdowns into 2021.
Yet many experts are questioning whether current research and manufacturing efforts can deliver these medical breakthroughs as quickly as they are being promised. They also warn that anything short of a truly global effort to reach at-risk individuals in richer and poorer countries alike risks prolonging the pandemic, as well as supply and demand constraints, into the future.
